Acurx Pharmaceuticals, Inc. (ACXP)Healthcare | Biotechnology | Staten Island, United States | NasdaqCM
1.58 USD
+0.08
(5.333%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.57 -0.01 (-0.010%) ⇩ (July 13, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:04 a.m. EDT
The immediate outlook is severely clouded by a relentless multi-year price collapse and deteriorating fundamentals. The stock has lost over 92% of its value over the last four years, with every single year showing negative returns, including a catastrophic 79% drop last year. While recent headlines mention clinical developments and a potential path to breakeven, the market has priced in significant distress, evidenced by a negative forward P/E and massive losses in both assets and equity. The balance sheet shows negative free cash flow and negative operating cash flow, indicating the company is burning through capital without generating returns. Although the beta suggests high volatility, the lack of a dividend and the structural decline in share price make this a high-risk speculative play rather than a viable investment. The statistical forecast models also lean slightly negative for the coming month, reinforcing the bearish technical picture. |
| Model | MAE |
|---|---|
| MSTL_90_115 ✓ | 0.269656 |
| AutoARIMA | 0.316862 |
| MSTL_115 | 0.338434 |
| AutoTheta | 0.372157 |
| MSTL_90 | 0.381858 |
| AutoETS | 0.422104 |
| MSTL | 0.467357 |
Forecast horizon: 60 days | Selected: MSTL_90_115
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.81 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.883 |
| Excess Kurtosis | -0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 6,790,426 |
| Forward P/E | -0.74 |
| Beta | -2.05 |
| Previous Name | Acurx Pharmaceuticals, LLC |
| Website | https://www.acurxpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.83552635 |
| Address1 | 259 Liberty Avenue |
| All Time High | 176.4 |
| All Time Low | 1.326 |
| Ask | 1.92 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 101,620 |
| Average Daily Volume3 Month | 114,029 |
| Average Volume | 114,029 |
| Average Volume10Days | 101,620 |
| Beta | -2.045 |
| Bid | 1.14 |
| Bid Size | 2 |
| Book Value | 2.069 |
| City | Staten Island |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.58 |
| Current Ratio | 3.775 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.6 |
| Day Low | 1.495 |
| Display Name | Acurx Pharmaceuticals |
| Earnings Call Timestamp End | 1,786,737,600 |
| Earnings Call Timestamp Start | 1,786,737,600 |
| Earnings Timestamp | 1,786,710,600 |
| Earnings Timestamp End | 1,786,710,600 |
| Earnings Timestamp Start | 1,786,710,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -2,464,387 |
| Eps Current Year | -1.97 |
| Eps Forward | -2.13 |
| Eps Trailing Twelve Months | -3.79 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.7678 |
| Fifty Day Average Change | -0.18779993 |
| Fifty Day Average Change Percent | -0.1062337 |
| Fifty Two Week Change Percent | -83.552635 |
| Fifty Two Week High | 9.96 |
| Fifty Two Week High Change | -8.38 |
| Fifty Two Week High Change Percent | -0.84136546 |
| Fifty Two Week Low | 1.326 |
| Fifty Two Week Low Change | 0.25400007 |
| Fifty Two Week Low Change Percent | 0.1915536 |
| Fifty Two Week Range | 1.326 - 9.96 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,627,800,000 |
| Float Shares | 4,169,150 |
| Forward Eps | -2.13 |
| Forward P E | -0.74178404 |
| Free Cashflow | -3,415,170 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02992 |
| Held Percent Institutions | 0.061680004 |
| Implied Shares Outstanding | 4,297,738 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-25 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,754,352,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. |
| Long Name | Acurx Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 6,790,426 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_558025934 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -7,498,327 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,446,607 |
| Number Of Analyst Opinions | 3 |
| Open | 1.51 |
| Operating Cashflow | -6,143,816 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 917 533 1469 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.6329108 |
| Post Market Price | 1.57 |
| Post Market Time | 1,783,986,972 |
| Prev Name | Acurx Pharmaceuticals, LLC |
| Previous Close | 1.5 |
| Price Eps Current Year | -0.80203044 |
| Price Hint | 4 |
| Price To Book | 0.76365393 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.685 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.08 |
| Regular Market Change Percent | 5.33334 |
| Regular Market Day High | 1.6 |
| Regular Market Day Low | 1.495 |
| Regular Market Day Range | 1.495 - 1.6 |
| Regular Market Open | 1.51 |
| Regular Market Previous Close | 1.5 |
| Regular Market Price | 1.58 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 104,274 |
| Return On Assets | -0.66498 |
| Return On Equity | -1.6083 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,297,738 |
| Shares Percent Shares Out | 0.0315 |
| Shares Short | 135,522 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 90,033 |
| Short Name | Acurx Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0326 |
| Short Ratio | 1.71 |
| Source Interval | 15 |
| State | NY |
| Symbol | ACXP |
| Target High Price | 31.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 10.0 |
| Total Cash | 9,254,813 |
| Total Cash Per Share | 2.153 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.79 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.2212 |
| Two Hundred Day Average Change | -1.6412 |
| Two Hundred Day Average Change Percent | -0.50949955 |
| Type Disp | Equity |
| Volume | 104,274 |
| Website | https://www.acurxpharma.com |
| Zip | 10,305 |